PURPOSE: To assess complications, local tumor recurrences, overall survival (OS), and estimates of cost-effectiveness for multisite cryoablation (MCA) of oligometastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 60 computed tomography- and/or ultrasound-guided percutaneous MCA procedures were performed on 72 tumors in 27 patients (three women and 24 men). Average patient age was 63 years. Tumor location was grouped according to common metastatic sites. Established surgical selection criteria graded patient status. Median OS was determined by Kaplan-Meier method and defined life-years gained (LYGs). Estimates of MCA costs per LYG were compared with established values for systemic therapies. RESULTS: Total number of tumors and cryoablation procedures for each anatomic site are as follows: nephrectomy bed, 11 and 11; adrenal gland, nine and eight; paraaortic, seven and six; lung, 14 and 13; bone, 13 and 13; superficial, 12 and nine; intraperitoneal, five and three; and liver, one and one. A mean of 2.2 procedures per patient were performed, with a median clinical follow-up of 16 months. Major complication and local recurrence rates were 2% (one of 60) and 3% (two of 72), respectively. No patients were graded as having good surgical risk, but median OS was 2.69 years, with an estimated 5-year survival rate of 27%. Cryoablation remained cost-effective with or without the presence of systemic therapies according to historical cost comparisons, with an adjunctive cost-effectiveness ratio of $28,312-$59,554 per LYG. CONCLUSIONS: MCA was associated with very low morbidity and local tumor recurrence rates for all anatomic sites, with apparent increased OS. Even as an adjunct to systemic therapies, MCA appeared cost-effective for palliation of oligometastatic RCC.
PURPOSE: To assess complications, local tumor recurrences, overall survival (OS), and estimates of cost-effectiveness for multisite cryoablation (MCA) of oligometastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 60 computed tomography- and/or ultrasound-guided percutaneous MCA procedures were performed on 72 tumors in 27 patients (three women and 24 men). Average patient age was 63 years. Tumor location was grouped according to common metastatic sites. Established surgical selection criteria graded patient status. Median OS was determined by Kaplan-Meier method and defined life-years gained (LYGs). Estimates of MCA costs per LYG were compared with established values for systemic therapies. RESULTS: Total number of tumors and cryoablation procedures for each anatomic site are as follows: nephrectomy bed, 11 and 11; adrenal gland, nine and eight; paraaortic, seven and six; lung, 14 and 13; bone, 13 and 13; superficial, 12 and nine; intraperitoneal, five and three; and liver, one and one. A mean of 2.2 procedures per patient were performed, with a median clinical follow-up of 16 months. Major complication and local recurrence rates were 2% (one of 60) and 3% (two of 72), respectively. No patients were graded as having good surgical risk, but median OS was 2.69 years, with an estimated 5-year survival rate of 27%. Cryoablation remained cost-effective with or without the presence of systemic therapies according to historical cost comparisons, with an adjunctive cost-effectiveness ratio of $28,312-$59,554 per LYG. CONCLUSIONS:MCA was associated with very low morbidity and local tumor recurrence rates for all anatomic sites, with apparent increased OS. Even as an adjunct to systemic therapies, MCA appeared cost-effective for palliation of oligometastatic RCC.
Authors: Peter J Littrup; Abraham Ahmed; Hussein D Aoun; Daniel L Noujaim; Ted Harb; Sam Nakat; Khaled Abdallah; Barbara A Adam; Raghu Venkatramanamoorthy; Wael Sakr; J Edson Pontes; Lance K Heilbrun Journal: J Vasc Interv Radiol Date: 2007-03 Impact factor: 3.464
Authors: Mohamad E Allaf; Ioannis M Varkarakis; Sam B Bhayani; Takeshi Inagaki; Louis R Kavoussi; Stephen B Solomon Journal: Radiology Date: 2005-08-26 Impact factor: 11.105
Authors: G Scott Gazelle; Pamela M McMahon; Molly T Beinfeld; Elkan F Halpern; Milton C Weinstein Journal: Radiology Date: 2004-12 Impact factor: 11.105
Authors: Geoffrey A Porter; Scott B Cantor; Garrett L Walsh; Valerie W Rusch; Dennis H Leung; Alma Y DeJesus; Raphael E Pollock; Murray F Brennan; Peter W T Pisters Journal: J Thorac Cardiovasc Surg Date: 2004-05 Impact factor: 5.209
Authors: James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Caroline J Simon; Damian E Dupuy; Thomas A DiPetrillo; Howard P Safran; C Alexander Grieco; Thomas Ng; William W Mayo-Smith Journal: Radiology Date: 2007-04 Impact factor: 11.105
Authors: Jason B Hartman; Nicholas Bhojwani; David J Corn; Matthew M Cooney; John Haaga; Lee Ponsky; Robert Abouassaly; Akshay Paspulati; J David Prologo Journal: J Vasc Interv Radiol Date: 2014-03-18 Impact factor: 3.464
Authors: Francois Cornelis; Philip B Paty; Constantinos T Sofocleous; Stephen B Solomon; Jeremy C Durack Journal: Cardiovasc Intervent Radiol Date: 2014-07-01 Impact factor: 2.740
Authors: Jesse J Veenstra; Heather M Gibson; Peter J Littrup; Joyce D Reyes; Michael L Cher; Akira Takashima; Wei-Zen Wei Journal: Cancer Res Date: 2014-08-04 Impact factor: 12.701
Authors: Peter J Littrup; Hyun J Bang; Brandt P Currier; Dylan J Goodrich; Hussein D Aoun; Lance K Heilbrun; Barbara A Adam Journal: J Vasc Interv Radiol Date: 2013-09-20 Impact factor: 3.464
Authors: Martin J Connor; Taimur T Shah; Gail Horan; Charlotte L Bevan; Mathias Winkler; Hashim U Ahmed Journal: Nat Rev Clin Oncol Date: 2019-11-11 Impact factor: 66.675